10x Genomics (TXG) Price & Analysis

Compare

1,208 Followers

TXG Stock Chart & Stats

$15.65

-$0.12(-0.77%)

At close: Jan 08 4:00 PM EST

$15.65

-$0.12(-0.77%)

Day’s Range― - ―

52-Week Range$6.78 - $17.70

Previous CloseN/A

Volume385.49K

Average Volume (3M)2.98M

Market Cap

$1.99B

Enterprise Value$1.07B

Total Cash (Recent Filing)$482.08M

Total Debt (Recent Filing)$86.98M

Price to Earnings (P/E)―

Beta1.64

Next Earnings

Feb 18, 2026

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.22

Shares Outstanding116,474,180

10 Day Avg. Volume3,777,153

30 Day Avg. Volume2,983,314

Financial Highlights & Ratios

PEG Ratio0.31

Price to Book (P/B)2.44

Price to Sales (P/S)2.83

P/FCF Ratio-301.92

Enterprise Value/Market Cap0.54

Enterprise Value/Revenue1.67

Enterprise Value/Gross Profit2.43

Enterprise Value/Ebitda-34.80

Forecast

1Y Price Target

$16.25

Price Target Upside3.83% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering10

EPS Forecast (FY)-0.52

Revenue Forecast (FY)$633.04M

Bulls Say, Bears Say

Bulls Say

Financial PerformanceTotal revenue for 3Q25 exceeded estimates and consensus, with particular strength in Chromium revenue.

Product Innovation10x Genomics recently launched new products, including next-gen Chromium Flex and Xenium Protein, highlighting a commitment to product innovation.

Strategic AcquisitionsThe acquisition of Scale Biosciences strengthens 10x Genomics' leadership position in single cell technology, expected to expand TXG's portfolio.

Bears Say

Budget ConstraintsA significant portion of TXG's revenue comes from the US academic market, which faces budget constraints affecting overall demand.

Market UncertaintyOngoing macro uncertainty continues to disrupt customer purchasing patterns and reduces visibility regarding the company's outlook.

Revenue TrendsRevenue was down 4% year-over-year and year-to-date, indicating challenges in maintaining growth momentum.

10x Genomics News

10x Genomics price target raised to $19 from $15 at Piper Sandler

Piper Sandler raised the firm’s price target on 10x Genomics (TXG) to $19 from $15 and keeps a...

9d ago

TXG

Cathie Wood Buys the Dip in Archer Aviation (ACHR) After Weak Q3 Results, Trims Stakes in Roku and TER Stocks

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio adjustments on Thursday, November 6, according to daily fund...

13d ago

TER

TXG

10x Genomics price target raised to $14 from $13 at UBS

UBS raised the firm’s price target on 10x Genomics (TXG) to $14 from $13 and keeps a Neutral...

13d ago

TXG

10x Genomics price target raised to $15 from $13 at JPMorgan

JPMorgan raised the firm’s price target on 10x Genomics (TXG) to $15 from $13 and keeps a Neutral...

13d ago

TXG

10x Genomics price target raised to $19 from $16 at Canaccord

Canaccord raised the firm’s price target on 10x Genomics (TXG) to $19 from $16 and keeps a Buy...

13d ago

TXG

10x Genomics price target raised to $17 from $15 at Barclays

Barclays analyst Luke Sergott raised the firm’s price target on 10x Genomics (TXG) to $17 from $15 and...

13d ago

TXG

10x Genomics reports Q3 EPS (22c) vs. (30c) last year

Reports Q3 revenue $149.0M, consensus $142.52M. Cash and cash equivalents and marketable securities were $482.1M as of September...

14d ago

TXG

10x Genomics sees Q4 revenue $154M-$158M, consensus $151.05M

16:28 EST 10x Genomics (TXG) sees Q4 revenue $154M-$158M, consensus $151.05M Published first on TheFly – the ultimate...

14d ago

TXG

Cathie Wood Pours into Veracyte Stake ahead of Earnings Beat, Slashes Biotech Holdings

Cathie Wood’s Ark Invest has made a series of portfolio adjustments. The firm trimmed exposure to several biotech...

15d ago

TXG

CRSP

Cathie Wood Boosts Biotech and DraftKings Stakes, Trims Shopify

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio adjustments on Wednesday, October 29, according to...

21d ago

TXG

ARKG

Cathie Wood’s ARK Investment buys 222K shares of 10x Genomics today

20:05 EDT Cathie Wood’s ARK Investment buys 222K shares of 10x Genomics (TXG) today Published first on TheFly...

22d ago

TXG

Cathie Wood Trims Exposure to AMD and Other U.S. Tech Favorites, Doubles Down on Baidu and Biotech Plays

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) revealed several key portfolio moves for Friday, October 24, 2025, according to ARK’s daily...

24d ago

AMD

TEM

10x Genomics Announces Chief Legal Officer Retirement

10x Genomics ( ($TXG) ) has provided an update. On November 12, 2025, Eric S. Whitaker announced his...

6d ago

TXG

10X Genomics Earnings Call: Mixed Results Amid Challenges

10X Genomics (($TXG)) has held its Q3 earnings call. Read on for the main highlights of the call....

13d ago

TXG

TXG FAQ

What was 10x Genomics Inc’s price range in the past 12 months?

10x Genomics Inc lowest stock price was $6.78 and its highest was $17.70 in the past 12 months.

What is 10x Genomics Inc’s market cap?

10x Genomics Inc’s market cap is $1.99B.

When is 10x Genomics Inc’s upcoming earnings report date?

10x Genomics Inc’s upcoming earnings report date is Feb 18, 2026 which is in 90 days.

How were 10x Genomics Inc’s earnings last quarter?

10x Genomics Inc released its earnings results on Nov 06, 2025. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.068.

Is 10x Genomics Inc overvalued?

According to Wall Street analysts 10x Genomics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does 10x Genomics Inc pay dividends?

10x Genomics Inc does not currently pay dividends.

What is 10x Genomics Inc’s EPS estimate?

10x Genomics Inc’s EPS estimate is -0.22.

How many shares outstanding does 10x Genomics Inc have?

10x Genomics Inc has 116,474,180 shares outstanding.

What happened to 10x Genomics Inc’s price movement after its last earnings report?

10x Genomics Inc reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went up 17.308%.

Which hedge fund is a major shareholder of 10x Genomics Inc?

Currently, no hedge funds are holding shares in TXG

10x Genomics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-10.12%

Trailing 12-Months

Asset Growth

9.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

10x Genomics Inc

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

10x Genomics (TXG) Earnings & Revenues

Historic Earnings Reports

TXG Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mixed picture, with strong performance in spatial consumables and successful new product launches offset by declines in overall revenue and instrument sales. Ongoing macroeconomic challenges and funding uncertainties continue to pose challenges.View all TXG earnings summaries

TXG Revenue Breakdown

60.32% Americas

22.99% EMEA

8.45% Asia-Pacific excluding China

8.24% China

TXG Stock 12 Month Forecast

Average Price Target

$16.25

▲(3.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","20":"$20","10.25":"$10.25","13.5":"$13.5","16.75":"$16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,10.25,13.5,16.75,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.64,14.052307692307693,14.464615384615385,14.876923076923077,15.28923076923077,15.701538461538462,16.113846153846154,16.526153846153846,16.93846153846154,17.35076923076923,17.763076923076923,18.175384615384615,18.587692307692308,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.64,13.840769230769231,14.041538461538462,14.242307692307692,14.443076923076923,14.643846153846154,14.844615384615384,15.045384615384616,15.246153846153847,15.446923076923078,15.647692307692308,15.848461538461539,16.049230769230768,{"y":16.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.64,13.667692307692308,13.695384615384615,13.723076923076924,13.750769230769231,13.778461538461539,13.806153846153846,13.833846153846155,13.861538461538462,13.88923076923077,13.916923076923077,13.944615384615386,13.972307692307693,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.47,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.37,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.39,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >